Martinsried – SuppreMol GmbH has enrolled the first patient in a Phase Ib/IIa clinical trial with SM101, a treatment for Idiopathic Thrombocytopenic Purpura (ITP). Up to 36 patients will receive 4 weekly doses of the recombinant, soluble, non-glycosylated version of the Fcg receptor IIb, or matching placebo intravenously. Subsequently, SuppreMol plans to enroll an additional 15 patients to expand the study to a Phase IIa parallel-group clinical trial. Primary endpoint is the incidence of adverse events. The main efficacy endpoint is the proportion of subjects with a substantial platelet response. Secondary endpoints comprise number of bleeding events, time to reach platelet response, duration of platelet response, proportion of subjects with rescue medication, and dose reduction of concomitant ITP medication.